To date, acquired immunodeficiency syndrome (AIDS) remains one of the largest global public health issues. The Human Immunodeficiency Virus (HIV), which is the causative agent of AIDS, has claimed over 40 million lives so far. The current standard of treatment is the combined antiretroviral therapy (cART), which suppresses viral replication. As a result, AIDS has shifted from a fatal disease to a highly treatable chronic condition. However, cART may cause severe side effects and is a life-long treatment, as it does not provide a functional cure, making the life-time medical cost of managing HIV very expensive for both the individual and the society. Additionally, the HIV/AIDS pandemic can have a significant socio-economic impact on a country, with job loss, reduced income, and high school dropout rates due to stigma and discrimination, which may lead to poverty, particularly affecting women and young people. Furthermore, low-and-middle income countries also face logistical challenges to supply all communities with anti-HIV medication, which is reflected in the fact that today only 75% of all HIV-patients are accessing treatment. Taking this together, there is an urgent need for a logistically feasible functional cure strategy to tackle the burden of the global HIV/AIDS pandemic. This thesis project focuses on developing a targeted protein treatment, based on a strategy that is currently applicable as cancer treatment and aims at helping the immune system to eradicate HIV reservoirs. Compared to vaccination, this approach will be more expensive, but still less costly than cell-based therapy. Overall, a definitive HIV cure would probably be more affordable than the present life-long antiviral therapy.